Information Request

About Us

3711 Market St

Integral Molecular is a research-driven biotechnology company creating innovative technologies and a pipeline of therapeutic antibodies for under-exploited membrane protein targets, including GPCRs, ion channels, transporters, and viral envelopes. The Company has over a decade of experience in optimizing membrane proteins, enabling the isolation, characterization, and engineering of monoclonal antibodies against otherwise intractable membrane protein targets. Integral Molecular has worked with over 100 different partners and customers, including all of the top 10 pharmaceutical companies.

Integral membrane proteins include some of the most important therapeutic targets. Yet these types of proteins are very difficult to study due to their structural complexity and inability to be removed from the lipid membrane in conformationally-intact states. At Integral Molecular, we develop innovative technologies and products that address these demanding yet important targets.

Founded in 2001, Integral Molecular holds intellectual property rights covering all aspects of its technologies, including core patents licensed exclusively from the University of Pennsylvania.

Research Facilities

Integral Molecular operates a 10,000-square-foot facility equipped with state-of-the-art molecular biology, cell culture, high-throughput robotics, biosensor, and flow cytometry instrumentation for a wide range of discovery capabilities. Integral Molecular is strategically located in the heart of Philadelphia’s University City Science Center within walking distance of $1B of scientific research, infrastructure, and expertise at the University of Pennsylvania, Drexel University, Children’s Hospital of Philadelphia, Wistar Institute, and Thomas Jefferson University.

  • Production Flasks
  • Robotics
  • Robotics
  • Labspace
  • 3711

Benjamin Doranz

Benjamin Doranz, Ph.D., MBA

President and CEO
Ben Doranz is President and CEO of Integral Molecular. Dr. Doranz co-founded the company in 2001 and has led all aspects of the company’s growth since its inception, bringing three different technologies from research to market and growing the company into a profitable commercial entity. He is an inventor on six of the company’s patents, the principal investigator on over 20 NIH grants, and an author on over 50 publications, including articles published in Cell, Science, and Nature.

Dr. Doranz is an established life science entrepreneur previously responsible for directing the biotechnology program at the Port of Technology business incubator in Philadelphia and helping create startups at the Center for Technology Transfer at the University of Pennsylvania. Dr. Doranz earned a Ph.D. in Cellular and Molecular Biology from the University of Pennsylvania where he led the discovery of the coreceptor for HIV (CCR5), an MBA at the Wharton School of Business where he won the business plan competition and co-founded the Penn Biotech Group, and a B.A. at Cornell University.

Joseph Rucker

Joseph Rucker, Ph.D.

VP of Research and Development
Joe Rucker is VP of Research & Development and a co-founder of Integral Molecular. Dr. Rucker is an inventor of Integral Molecular’s founding technology, the Lipoparticle, and was the first to use such particles as biochemical reagents. Since joining the company full-time in 2006, he has led the development of new applications for Lipoparticle technology, including its use for generating novel antibodies against membrane proteins.

Dr. Rucker’s expertise focuses on membrane proteins, antibodies, and viruses. He is an author on over 30 publications and has published in journals including Cell, Science, and Nature. He is an inventor on five of the company’s patents and is the principal investigator on many of Integral’s NIH-funded projects. Dr. Rucker earned his Ph.D. in Chemistry from the University of California, Berkeley and his B.A. at Haverford College. As a post-doc at the University of Pennsylvania, he was involved in leading the discovery of the GPCR CCR5 as an HIV coreceptor.

Sharon Willis

Sharon Willis, Ph.D.

VP of Sales and Customer Relations
Sharon Willis is VP of Technical Sales and Customer Support and a co-founder of Integral Molecular. Dr. Willis has been involved in all aspects of product development, from research and application development in the lab, through manufacturing, quality control, sales, and customer support. Her expertise has been instrumental in launching the company’s products and successfully placing Integral’s technologies with hundreds of customers world-wide, including all of the top pharmaceutical and biotechnology companies.

Dr. Willis is an adjunct professor in the Biology Department at Drexel University and a member of the Advisory Committee for the Biomedical Technical Training Program at the Wistar Institute. She is also a member of the External Advisory Board for the Chemistry Department at the University of North Carolina, Chapel Hill. Dr. Willis earned her Ph.D. in Chemistry from the University of North Carolina, Chapel Hill and her B.A. cum laude from Gettysburg College. As a post-doc at the University of Pennsylvania, she studied membrane-enveloped viruses and solved the crystal structure of the cellular receptor for HSV (gD-HVEM).

Ross Chambers

Ross Chambers, Ph.D.

Director of Antibody Discovery
Ross Chambers directs all antibody discovery projects at Integral Molecular. He brings over a decade of experience in industry leading the discovery of more than 2,000 antibodies. Dr. Chambers pioneered the use of DNA immunization for the production of antibodies in 2003, commercialized Genomic Antibody Technology (GAT) for the rapid isolation of antibodies, and developed the Picodroplet cloning system for the isolation of antibodies directly from B cells.

Dr. Chambers was previously the Director of Research and Development at SDIX, where he directed the discovery of thousands of commercial antibodies using DNA immunization, B cell cloning, and other isolation techniques. Before that he developed DNA immunization for large-scale antibody isolation projects at UT Southwestern. Dr. Chambers earned his Ph.D. from the University of Otago, New Zealand, and completed post-docs at UC Davis and Berkeley.

Dawn Eringis

Dawn Eringis, MBA

Business Development Officer
Dawn Eringis serves as Business Development Officer for Integral Molecular. She brings over 25 years of biotechnology/pharmaceutical industry experience encompassing major pharmaceutical to start-up biotechnology companies. Her career has spanned positions in business development, strategic planning, commercialization, marketing, and product management. Dawn has led or been directly involved in over $500 million worth of corporate licensing deals in the healthcare industry, encompassing both in-licensing and out-licensing of preclinical assets. Dawn previously co-founded and served as V.P. Business Development and Scientific Affairs for the biotechnology company PolyMedix, and served as Director of Business Development for Locus Pharmaceuticals. She holds an M.B.A. from the Wharton School of Business, and a B.S. degree in Chemical Engineering from the University of Pennsylvania.

Martin Phillips

Martin Phillips, M.D.

Advisor, Preclinical Development
Dr. Martin Phillips serves as Integral Molecular’s Advisor for Preclinical Development. Dr. Phillips is responsible for designing preclinical studies for antibody efficacy and safety enabling submission of investigational new drug (IND) applications. Dr. Phillips brings nearly 30 years of experience to this position including a career in academic medicine, biotech and the pharmaceutical industry. Previously, Dr. Phillips served as the Chief Medical Officer of Morphotek (now Eisai) and Atterocor (now Millendo Therapeutics). He has been responsible for numerous IND filings, negotiations with the FDA, and overseeing over 30 clinical studies globally involving biologics and small molecule therapeutics.

Shahram Hejazi

Shahram Hejazi, Ph.D.

Chair of Advisory Board
Shahram Hejazi serves as Chair of Integral Molecular’s advisory board, bringing over 20 years of industry experience. He has been working with Integral Molecular since 2011, guiding strategic, operational, and sales decisions. As a Venture Partner with BioAdvance, he focuses on investments in devices, diagnostics, research tools and health IT, and is a Director on the Board of six biotechnology companies. He is also the founder and CEO of Optimeos Life Sciences, a nanoparticle technology company. Dr. Hejazi is a life science entrepreneur and executive with experience in early-stage ventures and large global companies. Dr. Hejazi was previously the President of Kodak's Molecular Imaging division, the CEO of Zargis Medical, and the Global Head of the Strategic Business Development at Siemens Medical. Dr. Hejazi earned his Ph.D. in Electrical Engineering from SUNY-Buffalo and an executive business education from Stanford University.

Janis von Culin

Janis von Culin, M.S.

Advisor, Human Resources
Janis von Culin provides human resources guidance to Integral Molecular and is a member of its business advisory board. Ms. von Culin works closely with management and staff in developing and implementing human resource programs in leadership effectiveness, staffing and selection, and performance management. Ms. von Culin previously worked 18 years with Avery Dennison, a Fortune 500 manufacturing and distribution corporation. As Group Director of Human Resources, she led the HR function for nine divisions operating in North America and Asia. Ms. Von Culin holds a Bachelor’s degree in human development from Pacific Oaks College and a Master’s degree in psychology from California State University at Los Angeles.

James Augusterfer

James Augusterfer, M.S., EA

Jim Augusterfer is the financial Controller at Integral Molecular, responsible for establishing and maintaining financial records and audit-compliance for the company’s internal records, taxes, and external funding sources. Mr. Augusterfer earned his B.S. in Accountancy from West Chester University, his Masters of Science-Taxation from Villanova University, and his Certificate of Enrollment from the Internal Revenue Service.

Scientific Advisory Board

Greg Adams, Ph.D.

Chief Development Officer, Eleven Biotherapeutics

Martin Lehr

President and Chief Business Officer, Context Therapeutics

Don Siegel, M.D., Ph.D.

Professor of Pathology and Laboratory Medicine, Hospital of the University of Pennsylvania

Michael O'Leary, Ph.D.

Associate Professor of Biomedical Sciences, Cooper Medical School of Rowan University